Executive Summary: EHC Round Table on “Current Issues in von Willebrand Disease”

content-logo-colorfull

On 10 September 2024, the EHC hosted its first post-pandemic Round Table on “Current Issues in von Willebrand Disease” in Brussels, Belgium. The event took place at the Warwick Hotel from 13:00 to 16:30, and was co-chaired by Miguel Crato, EHC President, and Dr Maria Elisa Mancuso, Chair of the EHC Medical Advisory Group.

The Round Table was attended by a diverse group of stakeholders. This included EHC staff and Steering Committee members, National Member Organisation (NMO) representatives, and members of the EHC Von Willebrand Disease (VWD) Committee. In addition, third-party organisations such as the European Association for Haemophilia and Allied Disorders (EAHAD), clinicians, and industry representatives were present.

The variety of attendees fostered rich discussions and allowed for a broad exchange of perspectives on the key challenges and opportunities in VWD care.

Other resources

Reflecting on 2025: a year of consolidation

Throughout 2025, we have strengthened our foundations as a credible and mature organisation, reinforced our collective voice, and further clarified our role in supporting National Member Organisations (NMOs) across Europe.

content-logo-colorfull

Update on Novo Nordisk manufacturing deviation for NovoSeven©, resulting in shortages for NovoEight© and Esperoct©

Mid-June 2024, the EHC, NBDF and WFH were made aware of a manufacturing deviation in the production lines of several products for the treatment of haemophilia and other coagulopathies manufactured by Novo Nordisk in Denmark.

content-logo-colorfull